1-3 of 3
Francis A. Ayuk
Close
Sort by
Journal Articles

Chimeric antigen receptor T-cell therapy and fludarabine: precision dosing imperatives

Clinical Trials & Observations
Sebastian G. Wicha, Eva M. A. Wansing, Adrin Dadkhah, Francis A. Ayuk, Nicolaus M. Kröger, Claudia Langebrake
Journal: Blood Advances
Blood Adv (2024) 8 (3): 797–798.
https://doi.org/10.1182/bloodadvances.2023012068
Published: 2024
Journal Articles

Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study

Maria-Luisa Schubert, Wolfgang A. Bethge, Francis A. Ayuk, Malte von Bonin, Vladan Vucinic, Eva Marie Wagner-Drouet, Marion Subklewe, Claudia D. Baldus, Bertram Glass, Reinhard Marks, Dimitrios Mougiakakos, Roland Schroers, Matthias Stelljes, Max S. Topp, Gerald Wulf, Nicolaus Kröger, Peter Dreger
Journal: Blood Advances
Blood Adv (2023) 7 (20): 6191–6195.
https://doi.org/10.1182/bloodadvances.2023011203
Published: 2023
Includes: Supplemental data
Journal Articles

Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting

Clinical Trials & Observations
Francis A. Ayuk, Carolina Berger, Anita Badbaran, Tatjana Zabelina, Tanja Sonntag, Kristoffer Riecken, Maria Geffken, Dominic Wichmann, Christian Frenzel, Guenther Thayssen, Silke Zeschke, Nicolaus Kröger, Boris Fehse
Journal: Blood Advances
Blood Adv (2021) 5 (11): 2523–2527.
https://doi.org/10.1182/bloodadvances.2020003959
Published: 2021
Includes: Supplemental data